DK0999826T3 - Selv-emulgerende formulering til lipofile forbindelser - Google Patents

Selv-emulgerende formulering til lipofile forbindelser

Info

Publication number
DK0999826T3
DK0999826T3 DK98936889T DK98936889T DK0999826T3 DK 0999826 T3 DK0999826 T3 DK 0999826T3 DK 98936889 T DK98936889 T DK 98936889T DK 98936889 T DK98936889 T DK 98936889T DK 0999826 T3 DK0999826 T3 DK 0999826T3
Authority
DK
Denmark
Prior art keywords
diglyceride
monoglyceride
self
emulsifying formulation
lipophilic compounds
Prior art date
Application number
DK98936889T
Other languages
Danish (da)
English (en)
Inventor
Walter Morozowich
Ping Gao
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of DK0999826T3 publication Critical patent/DK0999826T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Silicon Polymers (AREA)
DK98936889T 1997-07-29 1998-07-27 Selv-emulgerende formulering til lipofile forbindelser DK0999826T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5401297P 1997-07-29 1997-07-29
US5407897P 1997-07-29 1997-07-29
PCT/US1998/014818 WO1999006024A1 (en) 1997-07-29 1998-07-27 Self-emulsifying formulation for lipophilic compounds

Publications (1)

Publication Number Publication Date
DK0999826T3 true DK0999826T3 (da) 2004-07-26

Family

ID=26732506

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98936889T DK0999826T3 (da) 1997-07-29 1998-07-27 Selv-emulgerende formulering til lipofile forbindelser

Country Status (23)

Country Link
EP (1) EP0999826B1 (xx)
JP (2) JP2002511099A (xx)
KR (1) KR100509776B1 (xx)
CN (1) CN1208047C (xx)
AT (1) ATE265847T1 (xx)
AU (1) AU728698B2 (xx)
BR (1) BR9811058A (xx)
CA (1) CA2294031E (xx)
CZ (1) CZ297206B6 (xx)
DE (1) DE69823663T2 (xx)
DK (1) DK0999826T3 (xx)
ES (1) ES2219895T3 (xx)
FI (1) FI20000170A (xx)
HK (1) HK1028883A1 (xx)
HU (1) HU226114B1 (xx)
NO (1) NO328591B1 (xx)
NZ (1) NZ502569A (xx)
PL (1) PL191780B1 (xx)
PT (1) PT999826E (xx)
RU (1) RU2211021C2 (xx)
SI (1) SI0999826T1 (xx)
SK (1) SK284511B6 (xx)
WO (1) WO1999006024A1 (xx)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
DK0999838T3 (da) * 1997-07-29 2002-07-08 Upjohn Co Selv-emulgerende formulering for lipofile forbindelser
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19912436A1 (de) * 1999-03-19 2000-09-21 Merckle Gmbh Ibuprofen-Lösung
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
EP1479382A1 (en) * 1999-06-18 2004-11-24 IVAX Research, Inc. Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
GB2355656B (en) * 1999-08-17 2004-04-07 Galena As Pharmaceutical compositions for oral and topical administration
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
KR100425755B1 (ko) * 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
DE60313299T2 (de) * 2002-03-01 2008-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Selbstemulgierende systeme zur abgabe von taxoiden
EP1340497A1 (en) * 2002-03-01 2003-09-03 Novagali Sas Self emulsifying drug delivery systems for poorly soluble drugs
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
KR100573289B1 (ko) * 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
JP2006521366A (ja) * 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
ES2393814T3 (es) 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
WO2008132707A1 (en) 2007-04-26 2008-11-06 Sigmoid Pharma Limited Manufacture of multiple minicapsules
PT2868315T (pt) 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
WO2009097443A2 (en) * 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
JP2011520921A (ja) * 2008-05-16 2011-07-21 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍アルカロイドとの併用療法
EP2204167A1 (en) * 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
DK2471518T3 (en) 2009-05-18 2017-12-04 Sigmoid Pharma Ltd COMPOSITION INCLUDING OIL DROPS
ES2464367T3 (es) * 2009-07-07 2014-06-02 Boehringer Ingelheim International Gmbh Composición Farmacéutica para un Inhibidor de Proteasa del Virus de la Hepatitis C
IN2012DN00781A (xx) 2009-08-12 2015-06-26 Sigmoid Pharma Ltd
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
AU2012209184B2 (en) * 2011-01-26 2017-06-15 Allergan, Inc. Androgen composition for treating an opthalmic condition
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
US9732083B2 (en) 2011-03-15 2017-08-15 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
ES2763352T3 (es) * 2013-01-14 2020-05-28 Infirst Healthcare Ltd Composiciones de solución sólida y uso en inflamación crónica
AU2014204739B2 (en) * 2013-01-14 2016-08-11 Infirst Healthcare Limited Compositions and methods for treating severe pain
BR112015015870B1 (pt) * 2013-02-04 2022-09-27 Infirst Healthcare Limited Uso de uma composição farmacêutica
WO2015031637A1 (en) * 2013-08-29 2015-03-05 Abbott Laboratories Nutritional composition having lipophilic compounds with improved solubility and bioavailability
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CN104706591B (zh) * 2013-12-16 2018-09-04 天津迈迪瑞康生物医药科技有限公司 一种前列地尔药物组合物、其制备方法及用途
US10143657B2 (en) * 2014-01-17 2018-12-04 Oncoral Pharma Aps Solid oral dosage form of irinotecan for the treatment of cancer
KR20170020779A (ko) 2014-06-17 2017-02-24 머크 샤프 앤 도메 비.브이. 테스토스테론 운데카노에이트의 안정한 제제
CN104274532A (zh) * 2014-10-21 2015-01-14 河南牧翔动物药业有限公司 复方灰黄霉素抗菌药物
EP3881829A1 (en) 2014-11-07 2021-09-22 Sublimity Therapeutics Limited Compositions comprising cyclosporin
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR101587385B1 (ko) * 2015-07-29 2016-01-21 국제약품공업주식회사 사이클로스포린 함유 무자극성의 안약조성물 및 편리한 제조방법
BR112018005315A2 (pt) 2015-09-17 2018-10-09 Jrx Biotechnology Inc abordagens para aprimorar hidratação ou umidificação de pele
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB981926A (en) * 1963-01-22 1965-01-27 Wm Stewart & Arnold Ltd Method of preparing liquid and dried egg
DE2556592C2 (de) * 1975-12-16 1986-10-09 A. Nattermann & Cie GmbH, 5000 Köln Arzneimittelzubereitungen auf Basis öliger Lösungen von Phospholipiden
US4338307A (en) * 1980-11-10 1982-07-06 Abbott Laboratories 2'-N-Des-β-lysyl antibiotic AX-127B-1 and 4-N-acyl and alkyl derivatives thereof
DE3629386A1 (de) * 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
EP0267617B1 (en) * 1986-11-14 1992-06-24 Theratech, Inc. Penetration enhancement with binary system of cell envelope disordering compounds and lower alcohols
CA2038744C (en) * 1990-03-23 2002-01-08 Yoshitomi Pharmaceutical Industries Ltd. Pharmaceutical composition containing slightly water-soluble drug
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
JPH0734724B2 (ja) * 1992-02-03 1995-04-19 日清製油株式会社 抱水性クリーム状組成物
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
EP1142568A1 (en) * 1992-09-25 2001-10-10 Novartis AG Pharmaceutical compositions containing cyclosporins
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
CA2221145A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
DE19537012A1 (de) * 1995-10-04 1997-04-10 Dietl Hans Cyclosporin(e) enhaltende pharmazeutische Zubereitung zur oralen Applikation und Verfahren zu ihrer Herstellung
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
DK0999838T3 (da) * 1997-07-29 2002-07-08 Upjohn Co Selv-emulgerende formulering for lipofile forbindelser

Also Published As

Publication number Publication date
EP0999826A1 (en) 2000-05-17
PT999826E (pt) 2004-09-30
CN1261790A (zh) 2000-08-02
AU728698B2 (en) 2001-01-18
CA2294031C (en) 2005-01-18
NO20000467L (no) 2000-03-29
SK284511B6 (sk) 2005-05-05
CZ297206B6 (cs) 2006-10-11
AU8573998A (en) 1999-02-22
HU226114B1 (en) 2008-04-28
WO1999006024A1 (en) 1999-02-11
NO20000467D0 (no) 2000-01-28
SI0999826T1 (en) 2004-12-31
NO328591B1 (no) 2010-03-29
DE69823663T2 (de) 2005-05-19
HK1028883A1 (en) 2001-03-09
JP5227301B2 (ja) 2013-07-03
DE69823663D1 (de) 2004-06-09
HUP0002486A1 (hu) 2000-12-28
JP2002511099A (ja) 2002-04-09
JP2010070562A (ja) 2010-04-02
ES2219895T3 (es) 2004-12-01
SK172000A3 (en) 2000-07-11
CA2294031E (en) 2012-04-03
RU2211021C2 (ru) 2003-08-27
NZ502569A (en) 2002-05-31
KR100509776B1 (ko) 2005-08-24
CA2294031A1 (en) 1999-02-11
CZ2000157A3 (cs) 2000-05-17
EP0999826B1 (en) 2004-05-06
BR9811058A (pt) 2000-09-05
HUP0002486A3 (en) 2001-03-28
FI20000170A (fi) 2000-01-28
PL338509A1 (en) 2000-11-06
CN1208047C (zh) 2005-06-29
ATE265847T1 (de) 2004-05-15
KR20010022365A (ko) 2001-03-15
PL191780B1 (pl) 2006-07-31

Similar Documents

Publication Publication Date Title
DK0999826T3 (da) Selv-emulgerende formulering til lipofile forbindelser
DK0999838T3 (da) Selv-emulgerende formulering for lipofile forbindelser
ES2529167T3 (es) Método para utilizar lípidos neutros para modificar la liberación in vivo desde liposomas multivesiculares
CL2009001870A1 (es) Composicion farmaceutica que comprende: a) un agente activo de prostaglandina que es 13,14-dihidro-15-ceto-20-etil-pgf2alfa isopropil ester, b) un primer tensoactivo no ionico, c) un segundo tensoactivo no ionico, d) un vehiculo oftalmicamente aceptable, util en el tratamiento de la hipertension ocular (divisional de la solicitud 557-98).
DK1173153T3 (da) Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
CY1105318T1 (el) Φαρμακευτικες συνθεσεις για απο του στοματος και τοπικη χορηγηση
MX9204382A (es) Composiciones
CO4970826A1 (es) Preparaciones de capsula suave que contienen ciclosporina
DK1154759T3 (da) Dispergerbart koncentrat til indgift af cyclosporin
AR021921A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos y budesonido.
CA2217767A1 (en) Low ph skin-treatment composition
AR017925A1 (es) Una formulacion acuosa para verter, topicamente aceptable, adaptada para su aplicacion externa localizada en un animal, su uso y un metodo para formularla
ATE396694T1 (de) O/w-emulsionen mit unpolaren wirkstoffen
BR9711501A (pt) Inibição viral por álcoois, alcanos, ácidos graxos e amidas de cadeia longa
BR9706804A (pt) Preparações de cápsula macia contendo ciclosporina.
ATE258427T1 (de) Pharmazeutische formulierungen enthaltend entzündungshemmende wirkstoffe und deren verwendung
PT1255535E (pt) Composicao farmaceutica de libertacao controlada contendo cloridrato de tramadol
KR950703333A (ko) 비이온계 계면활성제 함유 약학 조성물(Pharmaceutical Compositions Containing Nonionic Surfactants)